Evidence map›Paper›PMID 39473925›Full record

ArticleFrontiers in cellular and infection microbiology2024

ProcCluster® and procaine hydrochloride inhibit the growth of

Sarah König, Josefine Schroeder, Thorsten Heinekamp, Axel A Brakhage, Bettina Löffler, Beatrice Engert, Christina Ehrhardt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Procaine-Based ProcClusterInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sarah König *Section of Experimental Virology, Institute of Medical Microbiology, Center for Molecular Biomedicine (CMB), Jena University Hospital, Jena, Germany.
Josefine Schroeder *Section of Experimental Virology, Institute of Medical Microbiology, Center for Molecular Biomedicine (CMB), Jena University Hospital, Jena, Germany.
Thorsten HeinekampDepartment of Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knoell-Institute, Jena, Germany.
Axel A BrakhageDepartment of Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knoell-Institute, Jena, Germany.
Bettina LöfflerInstitute of Medical Microbiology, Jena University Hospital, Jena, Germany.
Beatrice EngertInflamed Pharma GmbH, Jena, Germany.
Christina EhrhardtSection of Experimental Virology, Institute of Medical Microbiology, Center for Molecular Biomedicine (CMB), Jena University Hospital, Jena, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Influenza-associated pulmonary aspergillosis is associated with high mortality rates and limited treatment options. The current standard practice involves treating each pathogen separately. However, the use of antifungal drugs can lead to serious side effects, and the presence of triazole-resistant Methods: Conidia of different Results: Both substances inhibited the growth of the fungus, even when applied after germination or in the presence of purified IAV particles. ProcCluster® remained effective against triazole-resistant Discussion: This research highlights ProcCluster® and procaine HCl as substances with anti-infective properties against various pathogens.

Indexed as

Antiviral AgentsCoinfectionInfluenza A virusProcaineA549 CellsAnimalsAntifungal AgentsAspergillusAspergillus fumigatusDogsEpithelial CellsHumansInfluenza, HumanMadin Darby Canine Kidney CellsMicrobial Sensitivity TestsProdrugsAntifungal AgentsAntiviral AgentsProcaineProdrugsaspergillosisAspergillus fumigatusinfluenza-associated pulmonary aspergillosisinfluenza viruslocal anestheticsprocaineProcCluster®

Identifiers

PMID39473925
PMCPMC11518849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.